Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Lijun Zhang et al.|The Lancet|2014Cited by 4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell LymphomaBhupinder Mann, Richard Pazdur, John R. Johnson et al.|The Oncologist|2007Cited by 1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsLeigh Marcus, Richard Pazdur, Steven J. Lemery et al.|Clinical Cancer Research|2019Cited by 1.2k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeRobert Q. Le, Richard Pazdur, Liang Li et al.|The Oncologist|2018Cited by 880
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.Peter Bross, Richard Pazdur, Julie Beitz et al.|PubMed|2001Cited by 861